NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Pfizer
Pfizer
Isofol Medical AB
Centro Nacional de Investigaciones Oncologicas CARLOS III
Eli Lilly and Company